Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)

To be considered for this study, you need to be an adult, aged 18 or older. The study is open to both men and women.

Because this is a specific type of lung cancer study, you would need to have been diagnosed with non-small cell lung cancer that is considered 'locally advanced,' meaning it has grown in the immediate area but isn't spread widely throughout your body, and it cannot be removed by surgery.

There will be other detailed medical checks to make sure the study is a safe and suitable option for you. These checks ensure that the treatment won't cause unnecessary risks and that the study results will be meaningful.

If you decide to take part in this study, you would first go through some initial medical checks. If eligible, you would start with a combination of chemotherapy and radiotherapy. This phase typically involves regular hospital visits for these treatments over several weeks.

After completing the chemotherapy and radiotherapy, your doctors will then decide which follow-up medicine you will receive – either MK-7684A or durvalumab. These are usually given as infusions, meaning the medicine is given directly into your bloodstream through a drip, typically over a set period of time at regular intervals. You would have regular appointments for these infusions and for check-ups to see how you are doing and to monitor for any side effects.

Taking part in a study like this usually involves multiple hospital visits over many months. This includes regular tests, scans, and discussions with the healthcare team to monitor your health and the progress of your treatment. The total duration of your participation could be quite long, potentially several years, including follow-up appointments.